Business
In addition to our clinical programs, we are advancing a pipeline of preclinical candidates for immunology and inflammation indications and aim to deliver a steady cadence of data for our new programs.
Evommune, Inc.: Revenue grew 85.7% to $13M from $7M. Net loss widened to $68.87M from $66.81M. Free cash flow outflow widened to $76.68M from $58.28M. Operating margin expanded 37657 bps to -623.62%. Evommune, Inc.'s annual comparison also shows free cash flow declined despite revenue growth; margins improved while free cash flow declined; stock compensation grew faster than revenue; capital spending grew faster than revenue.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 85.7% to $13M from $7MOK
- Profitability — Net loss widened to $68.87M from $66.81MWatch
- Cash flow — Free cash flow outflow widened to $76.68M from $58.28MWatch
- Margins — Operating margin expanded 37657 bps to -623.62%OK
- Accounting — Prior going-concern doubt alleviatedWatch
- Insiders — 4 purchases and 0 salesOK
Where the revenue comes from
Fiscal 2025, as Evommune, Inc. reports it. History and quarterly detail are in the app.
- Performance Obligation$3.0M
Latest filings
- 8-K · Company announcement2026-08-06
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-07-30
- 8-K · Company announcement2026-06-29
- 8-K · Company announcement2026-06-02
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Evommune, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.